Tandem Autologous- Nonmyeloablative Allogeneic Transplant for Newly Diagnosed Multiple Myeloma (Trapianto Tandem Autologo-Allogenico Non Mieloablativo Nel Mieloma Alla Diagnosi)

Allogeneic Stem Cell Transplantation for Multiple Myeloma: a Two Step Approach to Reduce Toxicity Involving High-Dose Melphalan and Autologous Stem Cell Transplant Followed by PBSC Allografting After Low-Dose TBI

To evaluate toxicity profile and efficacy of a tandem autologous-nonmyeloablative transplant approach in newly diagnose myeloma patients younger than 65 years

Inclusion Criteria:

• Durie-Salmon stage IIA-IIIB multiple myeloma
• Age > 18 and ≤ 65 years
• Previously untreated myeloma
• Presence of a sibling (potential donor)
• Bilirubins < twice normal;ALAT and ASAT < four times normal
• Left ventricular ejection fraction > 40%
• Creatinine clearances > 40 mL/min
• Pulmonary dysfunction with diffusing capacity for carbon monoxide (DLCO) > 40% and/or need for continuous oxygen supplementation
• Karnofsky performance status > 60%
• Patients must give written informed consent

Exclusion Criteria:

• Age > 65 years
• Previously treated myeloma
• Absence of a sibling (genetic randomisation cannot be applied)
• Karnofsky performance status score < 60%
• HIV-infection
• Pregnancy
• Refusal to use contraceptive techniques during and for 12 months following treatment
• Patients unable to give written informed consent
• PS. Informed consent is obtained from each patient according to the Institutional Review Boards of the participating centers. The study is conducted according to the Declaration of Helsinki.